Retatrutide is an investigational synthetic peptide developed by Eli Lilly that activates three metabolic hormone receptors at once — GLP-1, GIP, and glucagon — rather than the one or two targeted by earlier incretin-based compounds. In a 48-week phase 2 obesity trial, participants receiving the highest dose experienced an average body-weight reduction of 24.2%, an estimate from that specific trial population and analysis [3], and company-reported phase 3 extension results in 2026 reached roughly 30% over two years in a subgroup with baseline BMI ≥35 continuing treatment [10]. Parallel studies have reported substantial reductions in HbA1c in type 2 diabetes [4][8] and in liver fat in metabolic dysfunction-associated steatotic liver disease (MASLD) [5]. Retatrutide remains an investigational compound: it is not approved by the FDA for any use, and the material described here is a summary of the published scientific literature, not medical guidance.
What Is Retatrutide?
Retatrutide, known during early development as LY3437943, is a single-chain peptide engineered by Eli Lilly and Company. It is built on a glucose-dependent insulinotropic polypeptide (GIP) backbone, modified with a C20 fatty diacid moiety that extends its half-life to roughly six days, supporting once-weekly subcutaneous administration in clinical trials [1].
The compound's development history follows the standard trajectory of an incretin-class candidate:
- Discovery and preclinical work (published 2022). Coskun and colleagues at Lilly described the molecule's pharmacology in Cell Metabolism, reporting agonist activity at the human glucagon, GIP, and GLP-1 receptors, with weight-lowering and glucose-lowering effects in rodent models and early human proof-of-concept data [1].
- Phase 1b (2022). A multiple-ascending-dose trial in 72 people with type 2 diabetes, published in The Lancet, established dose-dependent glucose lowering, weight reduction of up to about 9 kg over 12 weeks at the highest dose tested, and a tolerability profile dominated by gastrointestinal events — consistent with the GLP-1 receptor agonist class [2].
- Phase 2 (2023). Two pivotal mid-stage trials were published in mid-2023: an obesity trial in the New England Journal of Medicine [3] and a type 2 diabetes trial in The Lancet [4], both detailed below.
- Phase 3 (2025–2026, ongoing). The TRIUMPH program in obesity and the TRANSCEND program in type 2 diabetes have been reading out since late 2025 [8][9][10][11], with a dedicated cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) running through approximately 2029 [12]. Lilly has stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 [11].
Mechanism of Action
Retatrutide is often called a "triple agonist" or "triple G" because it engages three receptors that each influence energy balance and glucose regulation:
- GLP-1 receptor (glucagon-like peptide-1). Activation enhances glucose-dependent insulin secretion, suppresses glucagon release when glucose is elevated, slows gastric emptying, and reduces appetite. This is the mechanism shared with semaglutide.
- GIP receptor (glucose-dependent insulinotropic polypeptide). GIP receptor activity contributes to insulin secretion and appears to modulate adipose tissue function; combining it with GLP-1 agonism is the innovation behind tirzepatide. In vitro, retatrutide shows greater potency at the GIP receptor than at the other two [1].
- Glucagon receptor. This is the component that distinguishes retatrutide from both semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP). Glucagon receptor agonism increases hepatic energy expenditure and lipid oxidation. In principle this adds an "energy-output" mechanism on top of the appetite-suppressing "energy-input" mechanisms, and it is the leading hypothesis for the unusually large liver-fat reductions observed in the MASLD substudy [5]. Because glucagon also raises hepatic glucose output, the molecule was engineered so that incretin activity counterbalances any hyperglycemic effect [1].
A dedicated pharmacology study confirmed that retatrutide meaningfully delays gastric emptying, with the largest effect after the first dose and partial attenuation over repeated dosing — a pattern typical of the incretin class [6].
Research Findings by Area
Weight and metabolic outcomes
The phase 2 obesity trial randomized 338 adults with obesity, or overweight plus at least one weight-related condition, to once-weekly retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo for 48 weeks [3]. Least-squares mean weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg), versus −2.1% with placebo. At the 12 mg dose, 100% of participants achieved at least 5% weight reduction, 93% at least 10%, and 83% at least 15% — against 27%, 9%, and 2% respectively for placebo [3]. Notably, weight curves had not clearly plateaued at 48 weeks.
Phase 3 topline results have since extended these findings. In TRIUMPH-1 (NCT05929066; 2,339 adults with obesity or overweight and a weight-related comorbidity, without diabetes), company-reported efficacy-estimand weight reduction at 80 weeks was 19.0% (4 mg), 25.9% (9 mg), and 28.3% (12 mg) versus 2.2% for placebo; in a 104-week extension among participants with BMI ≥35, participants continuing in the 12 mg group averaged 30.3% weight reduction; the separate 45.3% responder figure for losing at least 30% refers to week 80 [10]. In TRIUMPH-3 (NCT05882045; 1,949 adults with severe obesity and established cardiovascular disease), weight reduction at 80 weeks averaged 21.6% (9 mg) and 22.6% (12 mg) versus 3.2% for placebo [11]. In TRIUMPH-4, conducted in adults with obesity or overweight and knee osteoarthritis, the highest dose produced an average 28.7% weight reduction alongside improvements in knee pain and physical function [9]. These phase 3 figures are from company-reported topline announcements and, at the time of writing, await full peer-reviewed publication.
On body composition: a DXA substudy of the phase 2 diabetes trial (103 participants with evaluable scans) found dose-dependent fat-mass reductions of up to roughly 26% from baseline at the pooled 8 mg dose, versus 2.6% with dulaglutide and 4.5% with placebo, indicating that the majority of weight lost was fat mass [7].
Glycemic outcomes
The phase 2 type 2 diabetes trial (NCT04867785) randomized 281 adults (mean baseline HbA1c 8.3%) to retatrutide across a 0.5–12 mg dose range, placebo, or dulaglutide 1.5 mg for 36 weeks [4]. At 24 weeks, HbA1c fell by up to 2.02 percentage points at the 12 mg dose, versus essentially no change with placebo and −1.41 with dulaglutide; body weight at 36 weeks fell by up to 16.94% at the highest dose. The investigators characterized the glucose-lowering as clinically meaningful with a safety profile consistent with the GLP-1 class [4].
In phase 3, TRANSCEND-T2D-1 (537 adults with type 2 diabetes inadequately controlled on diet and exercise) reported HbA1c reductions at 40 weeks of 1.69, 1.86, and 1.94 percentage points at the 4 mg, 9 mg, and 12 mg doses respectively, versus 0.81 with placebo, alongside weight reductions of 11.5–15.3% versus 2.6% [8]. TRIUMPH-2 (NCT05929079; 1,152 adults with type 2 diabetes and obesity or overweight) reported average weight reduction of up to 20.8% and HbA1c reduction of up to 1.6 percentage points at 80 weeks in topline results [11]. An interesting pattern across programs is that weight loss in participants with type 2 diabetes, while large, is consistently smaller than in participants without diabetes — a phenomenon also seen with semaglutide and tirzepatide.
Liver outcomes
A phase 2a substudy published in Nature Medicine enrolled 98 participants from the obesity trial who had MASLD with at least 10% liver fat by MRI-PDFF [5]. Relative liver-fat reduction at 24 weeks ranged from approximately 43% (1 mg) to approximately 82% (8 mg and 12 mg). In the 12 mg group, 86% of participants achieved normal liver-fat content (below 5%). Liver-fat reduction correlated with improvements in insulin sensitivity and lipid measures [5]. These are among the largest pharmacological liver-fat reductions reported in a randomized trial, though the study measured fat content by imaging, not biopsy-confirmed resolution of steatohepatitis or fibrosis.
Cardiovascular and inflammatory markers
Across trials, participants receiving retatrutide experienced improvements in cardiometabolic risk markers. In TRIUMPH-3 — a population with established cardiovascular disease — the 12 mg dose was associated with average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, and 51.2% in high-sensitivity C-reactive protein [11]. Similar directional changes in blood pressure and lipids were reported in the phase 2 obesity trial [3] and in TRIUMPH-4 [9]. Whether these marker changes translate into fewer cardiovascular events is the question assigned to TRIUMPH-Outcomes (NCT06383390), an event-driven trial in adults with BMI ≥27 and atherosclerotic cardiovascular disease and/or chronic kidney disease, with major adverse cardiovascular events and kidney-function composites as primary endpoints and estimated completion around February 2029 [12].
Limitations & Open Questions in the Literature
- No approved indication. Retatrutide has completed phase 2 and several phase 3 trials, but it is not approved by any regulator; Lilly's stated FDA submission target is Q1 2027 [11]. All efficacy figures describe supervised clinical-trial settings.
- Topline versus peer-reviewed data. The TRIUMPH-1, -2, -3, and -4 results summarized above come from company press releases [9][10][11]. Full datasets, including complete adverse-event tables and secondary endpoints, had not all appeared in peer-reviewed journals at the time of writing.
- Tolerability and discontinuation. Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were the most common findings in every trial and were dose-related [2][3][4]. In TRIUMPH-1, 11.3% of 12 mg participants discontinued due to adverse events versus 4.9% on placebo; dysesthesia and urinary tract infections were also reported at modestly higher rates [10]. Heart-rate increases were observed in earlier trials and their long-term significance is not settled [3][4].
- Durability and regain. Published trials extend to 104 weeks at most [10]. What happens to weight, liver fat, and glycemia after discontinuation has not been characterized in the published retatrutide literature.
- Lean mass. The DXA substudy indicates most lost weight is fat [7], but lean-mass loss still occurs, and its functional consequences (strength, bone, sarcopenia risk in older adults) remain an open research question for the entire incretin class.
- Liver histology. The MASLD substudy used imaging endpoints; biopsy-verified effects on steatohepatitis and fibrosis await dedicated studies [5].
- Hard outcomes. Effects on cardiovascular events, kidney disease progression, and mortality are unknown pending TRIUMPH-Outcomes, which runs until roughly 2029 [12].
Frequently Asked Questions
What is retatrutide, in one sentence? An investigational once-weekly peptide from Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for obesity, type 2 diabetes, MASLD, and related conditions [1].
How does it differ from semaglutide and tirzepatide? Semaglutide targets one receptor (GLP-1), tirzepatide two (GLP-1 + GIP), and retatrutide three, adding glucagon receptor agonism, which increases hepatic energy expenditure and is hypothesized to drive its pronounced liver-fat effects [1][5].
How much weight loss has been reported in trials? In the phase 2 obesity trial, mean weight reduction reached 24.2% at 48 weeks at the highest dose [3]; company-reported efficacy-estimand results report 28.3% at 80 weeks, with 30.3% at 104 weeks in the extension subgroup with baseline BMI ≥35 continuing treatment [10], and 20.8% at 80 weeks in participants with type 2 diabetes [11].
Is retatrutide FDA-approved? No. It is an investigational compound in phase 3 development; the manufacturer has announced plans to file with the FDA in early 2027 [11].
What were the most common adverse events in trials? Dose-related gastrointestinal effects — nausea, diarrhea, vomiting, constipation — mostly mild to moderate and partially mitigated by lower starting doses; transient heart-rate increases were also observed [3][4].
What did the liver research show? In participants with MASLD, higher doses reduced liver fat by approximately 82% on average at 24 weeks, and most participants at those doses reached normal liver-fat levels by 48 weeks [5].
What major questions remain unanswered? Long-term durability, post-discontinuation effects, biopsy-confirmed liver outcomes, and whether risk-marker improvements translate into fewer cardiovascular and kidney events — the last being tested in a dedicated outcomes trial through ~2029 [12].
Storage and Stability
No peer-reviewed study has characterized the storage stability of retatrutide itself; formulation and stability data from the clinical development program remain proprietary to the manufacturer. Laboratory handling of research-grade material therefore follows general practice for synthetic peptides, for which the stability literature is well established [13]. Lyophilized peptides are far more stable than their solutions and are typically stored at −20 °C or below, desiccated and protected from light, with containers brought to room temperature before opening to avoid condensation on the powder. In solution, degradation pathways — hydrolysis, deamidation, oxidation, aggregation — proceed much faster, so reconstituted material (sterile water or a dilute neutral buffer is common laboratory practice) is generally held at 2–8 °C, used within a short window, and not subjected to repeated freeze–thaw cycles [13]. Retatrutide's C20 fatty-diacid modification [1] adds one further consideration: acylated peptides of this type can self-associate in aqueous solution, an additional reason laboratories minimize time spent in the solution state.
References
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID: 35985340
Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5. PMID: 36354040
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. PMID: 37366315
Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X. PMID: 37385280
Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi:10.1038/s41591-024-03018-2. PMID: 38858523
Urva S, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(10):2784–2788. doi:10.1111/dom.15167. PMID: 37311727
Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674–684. doi:10.1016/S2213-8587(25)00092-0. PMID: 40609566
Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407:2402–2413. doi:10.1016/S0140-6736(26)00967-0. PMID: 42250575
Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release, December 2025. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Press release, May 21, 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2, NCT05929079; TRIUMPH-3, NCT05882045). Press release, July 23, 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
ClinicalTrials.gov. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). NCT06383390. https://clinicaltrials.gov/study/NCT06383390
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6. PMID: 20143256
This article summarizes published scientific literature for educational purposes only. Retatrutide is an investigational compound not approved for human use. Nothing here constitutes medical advice, and no statement has been evaluated by the FDA.
